分级诊疗与即时检验(POCT)的发展机遇

2015-11-12 佚名 生物谷

2015年9月11日,国务院办公厅印发《关于推进分级诊疗制度建设的指导意见》,提出建立基层首诊、双向转诊、急慢分治、上下联动的分级诊疗模式,到2017年,分级诊疗政策体系逐步完善,医疗卫生机构分工协作机制基本形成,到2020年,分级诊疗服务能力全面提升,基本建立符合国情的分级诊疗制度。基于POCT(即时诊断设备及耗材)产品特点,将在分级诊疗建设体系建设中发挥重要的作用。 在11月19日-

2015年9月11日,国务院办公厅印发《关于推进分级诊疗制度建设的指导意见》,提出建立基层首诊、双向转诊、急慢分治、上下联动的分级诊疗模式,到2017年,分级诊疗政策体系逐步完善,医疗卫生机构分工协作机制基本形成,到2020年,分级诊疗服务能力全面提升,基本建立符合国情的分级诊疗制度。基于POCT(即时诊断设备及耗材)产品特点,将在分级诊疗建设体系建设中发挥重要的作用。

在11月19日-20日即将召开的2015 POCT产业发展论坛上,众多专家将围绕POCT发展的新机遇,新技术,新应用展开讨论。

中国医学装备协会及POCT专业委员会董书奎教授认为分级诊疗制度推行以后,将给POCT带来的发展机遇,主要表现在四点:一、POCT在三级医院的发展机遇:分级诊疗制度的实施,三级医院将出现患者向下分流,病种质量提高,病种数量减少、检验标本的数量大幅减少,三级医院检验科现有的全自动流水线、工作站式的大型检验平台将逐渐消失。应运而生的是POCT和区域检验检查中心。院内的标本:急诊科、麻醉科、ICU、心脏介入导管室、神经介入导管室、内科病房、外科病房等POCT大有用武之地;其余标本可有区域检验中心承担。 二、POCT在二级以下医院的发展机遇:POCT加常规国产检验设备即可满足需求,其余基本同三级医院。 三、POCT在社区卫生服务站或中心的发展机遇:由冷变热,常见病、多发病、慢性病的POCT数量明显增加。 四、POCT在家庭和个体化诊疗中的发展机遇:互联网+:POCT+移动医疗在家庭和个体化健康管理、疾病预防控制、慢病管理等方面引来井喷式的发展机遇。

2013年,全球POCT的市场规模约为100亿美元,平均增长速度在8%,中国约为5亿美元,占比低,增速在15%以上,远高于全球平均增长速度。

POCT产品市场主要集中在“血糖仪市场,妊娠检测,血气、电解质分析仪,疾病标志物检测”四类产品。血糖仪国产品牌市场占有率低,终端市场外资品牌占比50%以上,剩余的市场主要由三诺生物、北京怡成和鱼跃医疗等占据,但近年来国产品牌迅速发展,预计未来国产比例占比将迅速扩大,甚至超过国外产品占比;血气类产品主要以国外产品为主,主流产品中罕有国产品牌,理邦仪器已有相关产品推向市场;妊娠检测领域也是重要发展领域,随着居民生活方式的改变和优生优育意识的提升,妊娠检测类产品渗透率会有所提升;国家放开二胎的政策也有利于产品渗透率的提高,国产品牌主要有广州万孚生物,润和生物;

疾病标志物检测:POCT增速最快的子行业。2013年国际性领军企业在亚太地区的产品销售增速超过50%,是全球增速最快的地区,全球市场仍然被Alere,Roche和Abbott三家巨头垄断,国内厂商迅速崛起,主要代表厂商有:乐普医疗、南京基蛋、理邦仪器、深圳瑞莱、万孚生物等。

伴随着我国人口老龄化,二胎推行,居民健康意识的提升,医保覆盖范围及分级诊疗推进,等等诸多因素,我国POCT伴随即时诊断产品及试剂将迎来快速发展。

2015POCT产业论坛,将邀请邀请国内知名专家及企业齐聚太仓,讨论POCT的政策法规、市场分析、技术、产品、临床应用等诸多方面的话题,更多内容关注请关注2015(第四届)POCT产业发展论坛

附件:《中国POCT专家识》

现场快速检测(point-of-care testing,POCT)技术广泛应用于临床检验、慢病监测、应急反恐、灾害医学救援、传染病监测、检验检疫、食品安全、毒品检验等公共卫生领域。近年来,随着微纳制造、生物科技、新材料、移动互联网信息技术等高新技术的快速发展,使得POCT技术不断向实时、定量和检测设备小型化的方向发展。推动POCT产业的健康有序发展是时代赋予我们的崇高使命和责任。

1、POCT的定义

POCT是指在采样现场进行的、利用便携式分析仪器及配套试剂快速得到检测结果的一种检测方式。 POCT,在院内指在患者旁边进行的临床检测(床边检测bedside testing),通常不一定是临床检验师来进行。在院外则是指在采样现场即刻进行分析,省去标本在实验室检测时的复杂处理程序,快速得到检测结果的一类新方法。

POCT的特点决定了其应用场所极其广泛,既可放置于规范的实验室内,也可在出现在多种现场,包括大型医院的病房、门诊、急诊、检验科、手术室、监护室;基层医院、社区保健站和私人诊所;疾病预防控制中心、灾害医学救援现场、食品安全检测现场、环境保护现场;海关检疫、违禁药品快速筛查;法医学现场;生物反恐现场等。

2、POCT的特性和应用

2.1 POCT的特性

①快速获取结果,大大缩短样本周转时间(Turn Around Time,TAT)时间;

②仪器小型便携;

③使用标本微量,甚至不需要标本;

④操作简单,非专业人员经简单培训或阅读说明书即可操作;

⑤综合使用成本低。

2.2 POCT的应用

2.2.1 临床领域的应用

在临床领域,POCT的主要优势在于缩短样本周转时间(TAT),达到快速诊治的目的,缩短了患者在诊疗场所的停留时间。不仅提高了医疗工作效率,而且还使患者满意。

在医院内,POCT医学装备应用广泛,包括院内急诊科、ICU、呼吸科、心内科、手术室等临床科室。这种技术在时效性和灵活性方面与传统检验形成互补,也弥补了基层医院检验资源不足的问题。仅以急重症检验为例,POCT可以满足临床医生对这些指标快速准确报告的迫切需求,以便快速做出正确临床决策,挽救生命。

面对我国新一轮的医疗体制改革,在新农合医疗体系建设方面,POCT有望为突破大型进口设备的垄断,为提高基层特别是农村地区的医疗水平做出贡献。

虽然从“单个检验成本”方面考虑,POCT相对成本较高,但是临床应用POCT项目综合成本低,POCT可以降低资源的占用(包括病人住院的时间,采样时间,医护人员的占用时间等)。

2.2.2 健康管理领域的应用

家庭用血糖仪的广泛使用是POCT技术应用于慢病管理的一个成功典范。跨入新纪元以来,医疗模式与健康理念的转变成为了POCT发展的强大推动力。医疗历经了由家庭医疗、社区医疗、基层医院向大型中心级医院发展的历程,这是一种以疾病为中心的医疗模式。而在我们跨入本世纪以来,随着技术的发展,个体化医疗需求日益高涨,都使得以医院为核心集中资源、对症治疗的疾病诊疗模式逐步向家庭、社区日常保健回归的健康医疗模式发展。这对检验医学提出了检验设备小型化和检验方法简便化的明确需求。

应用POCT医疗服务的全新理念与远程医疗、可视化医疗等形成有机融合,为各级医疗受众群体提供人性化的医疗服务方式,建立新型医疗服务模式,为国家节约医疗服务资源、降低医疗服务成本等起到积极的促进作用。

2.2.3 生物应急领域的应用

POCT检测是在灾难处置中先遣急救者的首选。多年来,全球范围内处置突发事件和灾害事件的经验证明了POCT的作用和可行性。在传染病突发疫情处置、灾害医学救援、食品安全事故、生物反恐应急、检验检疫和违禁药品筛查等应急条件下,POCT为相关管理部门应急处置、急救实施、环境检测和预警启动等决策提供科学依据,为制订相应的预案奠定了基础。POCT满足了现场快速检测与应急处置的需求,即在“最短的时间”于“事发现场”实现可疑样品中“未知靶标”的快速定量检测,从而,能够提高生物应急的处置能力与标准。POCT无疑将为国家生物安全、人民健康、经济发展和社会稳定提供强有力的支撑。

2、POCT的发展与应用趋势

国际上POCT技术发展迅速,它是高新技术的缩影,是检测技术的集大成者。在世界范围内,新兴的POCT技术在临床医疗、生物应急、社区医疗乃至家庭慢病管理领域的应用及其管理都有一个发展过程。   近十年来,我国在此领域发展迅猛,但仍需要向先进国家学习科学的理念、先进的技术、市场应用管理政策。为推动我国POCT产业的发展,2012年,国务院印发关于生物产业发展规划、2011-2013年国家通过863计划、十二五科技项目计划大力支持POCT产业发展,极大地推动了我国POCT产业的迅速崛起。

3.1  POCT多样化

目前,市场上POCT主要应用的技术包括干化学技术、多层涂膜技术、免疫层析与渗滤技术(目前应用最广)、微流控技术、红外和远红外分光光度技术(不需采血可透皮连续监测血红蛋白和血糖等的技术)、选择性电极技术(主要用于检测血气和电解质)、生物传感器与生物芯片、微型显微镜成相模糊识别技术等等,测试对象也由生化指标、免疫指标逐步外延到核酸指标,目前市场上已有掌上PCR检测设备与试剂。

3.2  POCT技术从定性到定量

精确分析是检测技术发展的必然趋势。伴随新材料的不断涌现,并融合精密制造、生物医学、自动控制等多种新技术元素,新一代POCT具有可以和大型检测设备相媲美的精确定量能力。从而,迎来了POCT从定性或半定量到精确定量的新时代。以胶体金为示踪物的免疫层析产品是POCT定性技术的成功典范,包括早早孕、检测排卵等相关产品深刻影响了人类社会。在定量领域,包括普通荧光、时间分辨荧光、上转发光和电化学发光在内的多种发光技术为基础的检测试剂和设备已经实现了检测的精确定量。

3.3 对POCT的需求广泛

临床急诊、疾控应急、灾害救援、食品安全、生物反恐、进出口检疫和违禁药品筛查等对现场检验结果要求快速、准确,以便科学决策,合理处置;另外,医疗模式的转变,个体化医疗和家庭保健模式的发展对POCT技术提出了很高的要求。因此, POCT技术可以满足我们保障社会和经济安全发展、维护人民健康的需求。

3.4  POCT网络化

互联网特别是移动无线互联技术的发展,给POCT的发展带来了前所未有的机遇。已形成标准体系的大型设备无法走出实验室,无法走进家庭,无法来到患者的身边和事发现场。患者随时可使用POCT检测设备(甚至是可穿戴式)做检查,并将相关数据同步上传至后端诊疗服务云平台,线下医师服务团队通过平台调阅并判读检测数据,帮助患者诊断并提供用药指导和自我健康管理建议。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-09-29 zybear

    未来发展趋势,革新势在必行!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-08-27 李东泽

    这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-07-23 润世生物

    poct的质量,要加强

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-01-06 habb
  5. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-03-14 MDSC

    POCT的质量有待很好的控制

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-03-14 MDSC

    POCT的质量有待很好的控制

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2016-03-14 MDSC

    POCT的质量有待很好的控制

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    好学习很值得学

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-13 crystal 丁

    分级诊疗很实用

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=137707, encodeId=deb013e70761, content=未来发展趋势,革新势在必行!, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210720/81c525def1c4490db2c4d4fd31f4b910/367559b074d146aeab71188669c2396a.jpg, createdBy=3ec21628724, createdName=zybear, createdTime=Thu Sep 29 17:35:06 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=105928, encodeId=ad3c105928a6, content=这篇资讯带给我们新知识,启发新思维,不论是科研还是临床工作都有很大的帮助。。。, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sat Aug 27 22:27:00 CST 2016, time=2016-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94217, encodeId=44909421e8d, content=poct的质量,要加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160629/IMG57734040D79528125.jpg, createdBy=53541741718, createdName=润世生物, createdTime=Sat Jul 23 09:29:00 CST 2016, time=2016-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858311, encodeId=4e81185831138, content=<a href='/topic/show?id=21311323521' target=_blank style='color:#2F92EE;'>#OCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13235, encryptionId=21311323521, topicName=OCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19c567, createdName=habb, createdTime=Wed Jan 06 16:07:00 CST 2016, time=2016-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69467, encodeId=29a96946e86, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69469, encodeId=b44569469a5, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=69471, encodeId=3360694e104, content=POCT的质量有待很好的控制, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c31700233, createdName=MDSC, createdTime=Mon Mar 14 22:59:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49633, encodeId=fb1249633d4, content=好学习很值得学, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:42:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43119, encodeId=6d91431199c, content=分级诊疗很实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b5d1660826, createdName=crystal 丁, createdTime=Fri Nov 13 14:00:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43103, encodeId=d2ca4310374, content=分级诊疗需要得到好的实施,目前已经被乱用了……, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1571654784, createdName=高山2012, createdTime=Fri Nov 13 09:11:00 CST 2015, time=2015-11-13, status=1, ipAttribution=)]
    2015-11-13 高山2012

    分级诊疗需要得到好的实施,目前已经被乱用了……

    0

相关资讯

深圳公立医院改革权威解读:鼓励医生办诊所(附指标)

5月6日,国务院办公厅印发《关于城市公立医院综合改革试点的指导意见》。5月28日,深圳市按照国家的要求,在前期做好充分调研论证的基础上,在全国公立医院改革试点城市中率先出台《深圳市深化公立医院综合改革实施方案》(以下简称《实施方案》)。分级诊疗:动员医生强基层深圳市将优化以区域医疗中心和基层医疗服务网络的两层主体架构,而提高基层医疗服务能力是重点。为此,深圳市将优化社康中心布局,重点加强区域性

分级诊疗要落地 这几种模式你知道吗?

实现分级诊疗的模式有很多,移动医疗玩家们也给出了不同的思路,可谈论模式只是在为分级诊疗画饼,真的要实现分级诊疗还要看该如何落地,甚至说能否落地。当然,我们先来看一下目前备受关注的四种分级诊疗模式,他们之间有着怎样的共同点和不同之处。首先从被国内不少专家津津乐道的“美国模式”来讲。奥巴马的医改计划几度成为全球关注的热点,即便是医疗体系高度发达的美国依然面临一些医疗问题。美国医疗体系中得分级诊疗依

13名院士联合倡议支持医改分级诊疗,你怎么看?

根据国务院常务会议要求,今年我国所有公立医院改革试点城市和综合医改试点省份都要开展分级诊疗试点。在4日至5日于北京举行的2015年全科医学大会暨中华医学会全科医学分会第十三届年会上,十三名中国科学院及中国工程院院士联合倡议,发展全科医学、培训全科医师,支持分级诊疗。 王正国、王辰、付小兵、李兰娟、邱贵兴、陈香美、郎景和、赵玉沛、赵继宗、胡盛寿、钟南山、程京、赫捷等十三名院士在倡议书中提出,良

《关于推进分级诊疗制度建设的指导意见》明确分级诊疗政策明确推进时间点和标准

国务院办公厅关于推进分级诊疗制度建设的指导意见 国办发〔2015〕70号 各省、自治区、直辖市人民政府,国务院各部委、各直属机构: 建立分级诊疗制度,是合理配置医疗资源、促进基本医疗卫生服务均等化的重要举措,是深化医药卫生体制改革、建立中国特色基本医疗卫生制度的重要内容,对于促进医药卫生事业长远健康发展、提高人民健康水平、保障和改善民生具有重要意义。为贯彻落实《中共中央关于全面深化改革若

都说英国分级诊疗做得好,然后呢?

新医改进行六年多,大医院人滿为患,小医院医疗资源闲置,“看病难”仍普遍存在。政府为此将分级诊疗作为卫生医疗体制改革中的一项重要工作来抓。近日国务院医改办与相关部门组织专家组成12个督查组对国家试点县的29个省份开展督查,结果发现,补偿机制、价格调整、药品采购、医保支付、人事分配及管理机制等仍需加强。贯穿其中的分级诊疗制度及实施操作也未能发挥很好的设计作用,存在一定缺陷与弊端,需要进一步完善改进。我

医生收入到底高不高?

医生感慨自己的职业“高风险、高强度、低回报”,患者却抱怨看病贵看病难。如果说医生收入不高,普通百姓大概很难接受。然而,最近中国医师协会发布的《中国医师执业状况白皮书》中一组数据在新一轮医改启动的背景下不禁引人深思:被调查医师中65.9%对个人收入不满,月入过万者仅占6.15%;同时医师工作强度大,每周工作时间超过60小时者占32.69%。  5月17日国务院公布的《关于城市